{
  "ticker": "JNJ",
  "target_date": "2025-09-12",
  "actual_date": "2025-09-12",
  "collected_at": "2025-12-08T12:16:28.570731",
  "price": {
    "open": 176.59,
    "high": 177.67,
    "low": 175.61,
    "close": 176.93658447265625,
    "volume": 7220200,
    "change_1d_pct": -0.25,
    "change_7d_pct": 0.03,
    "change_30d_pct": 8.88
  },
  "technicals": {
    "rsi_14": 50.3,
    "sma_20": 176.07,
    "sma_50": 168.43,
    "macd": 2.25,
    "macd_signal": 2.774,
    "macd_histogram": -0.525,
    "bb_upper": 178.31,
    "bb_lower": 173.82,
    "price_vs_sma20_pct": 0.49,
    "price_vs_sma50_pct": 5.05,
    "volume_ratio": 0.91
  },
  "fundamentals": {
    "market_cap": 487653376000,
    "pe_ratio": 19.537163,
    "forward_pe": 19.09481,
    "price_to_book": 6.1433516,
    "price_to_sales": 5.2920094,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.6,
    "pct_from_52w_low": 43.88
  },
  "macro": {
    "spy": {
      "price": 655.59,
      "change_1d_pct": -0.03,
      "change_7d_pct": 1.28
    },
    "vix": {
      "level": 14.76,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.06
    },
    "dollar_index": {
      "level": 97.55
    },
    "gold": {
      "price": 3649.4
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra",
      "source": "Yahoo",
      "datetime": 1757694960,
      "summary": "J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.",
      "url": "https://finnhub.io/api/news?id=2a43ef0e0cc150979373bf87a86a1357fc6cfc401a2250527bd0b8b0e0e6c617"
    },
    {
      "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
      "source": "Yahoo",
      "datetime": 1757686860,
      "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448"
    },
    {
      "headline": "Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?",
      "source": "Yahoo",
      "datetime": 1757686080,
      "summary": "Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.",
      "url": "https://finnhub.io/api/news?id=3c0abd9f347cd4eea93e8c5222da62ae042bce6e2a949bc0f3e21b06637e4c01"
    },
    {
      "headline": "India's Vadilal Industries U.S. unit to make ice creams locally to cut imports",
      "source": "Yahoo",
      "datetime": 1757684753,
      "summary": "(Reuters) -The U.S. subsidiary of India\u2019s Vadilal Industries will start manufacturing ice cream at its local facility by the year-end to reduce dependence on imports and boost sales, an executive of the unit said on Friday.  Vadilal Industries USA currently imports a majority of its products from In",
      "url": "https://finnhub.io/api/news?id=453eaff4ee0f13858154a51162580e5eba9693c6f4dad1baf2024ca8d4ea7a87"
    },
    {
      "headline": "What Looms Ahead After The Dow Jones Topped A Record Of 46,000",
      "source": "SeekingAlpha",
      "datetime": 1757684698,
      "summary": "Dow Jones hits record 46,000 amid tech and AI gains. What does this mean for investors for the rest of this year? Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=7368aed8560d1a68ee92c89e62e983ce65e339a65d34a6156618d09607b13226"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627206.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000192/xslF345X05/wk-form4_1757627206.xml"
    },
    {
      "form": "8-K",
      "date": "2025-09-09",
      "description": "jnj-20250908.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm"
    },
    {
      "form": "4",
      "date": "2025-09-05",
      "description": "xslF345X05/wk-form4_1757109644.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000186/xslF345X05/wk-form4_1757109644.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}